Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Major Depressive Disorder
NCT05757791Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Mar 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in major depressive disorder (MDD), sponsored by NYU Langone Health. Started Mar 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05757791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757791.